The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21).
about
Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's diseaseCholinergic agonists regulate JAK2/STAT3 signaling to suppress endothelial cell activationα7 nicotinic ACh receptors as a ligand-gated source of Ca(2+) ions: the search for a Ca(2+) optimumStructural determinants for interaction of partial agonists with acetylcholine binding protein and neuronal α7 nicotinic acetylcholine receptorCholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's diseaseNicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disordersEffects of the nicotinic α7 receptor partial agonist GTS-21 on NMDA-glutamatergic receptor related deficits in sensorimotor gating and recognition memory in ratsR-(+) and S-(-) isomers of cotinine augment cholinergic responses in vitro and in vivo.Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking.Cognitive effects of nicotine: genetic moderators.Smoking, Genetics and Schizophrenia: Evidence for Self Medication.The 1-Tosylpentan-3-one Protects against 6-Hydroxydopamine-Induced NeurotoxicityActivation of functional α7-containing nAChRs in hippocampal CA1 pyramidal neurons by physiological levels of choline in the presence of PNU-120596Virtual screening against acetylcholine binding proteinCHRNA7 triplication associated with cognitive impairment and neuropsychiatric phenotypes in a three-generation pedigree.Cardiopulmonary arrest and resuscitation disrupts cholinergic anti-inflammatory processes: a role for cholinergic α7 nicotinic receptors.Treatment of dementia with neurotransmission modulation.Advances in pharmacotherapy for tobacco dependence.α7 Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer's Disease.A decade of e-cigarettes: Limited research & unresolved safety concernsSSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia.alpha7 nicotinic acetylcholine receptor agonist properties of tilorone and related tricyclic analogues.Modeling binding modes of alpha7 nicotinic acetylcholine receptor with ligands: the roles of Gln117 and other residues of the receptor in agonist binding.Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonistsPro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia.A type-II positive allosteric modulator of α7 nAChRs reduces brain injury and improves neurological function after focal cerebral ischemia in rats.Effects of tobacco smoke constituents, anabasine and anatabine, on memory and attention in female rats.Alzheimer's disease and age-related memory decline (preclinical)Synthesis and positron emission tomography studies of C-11-labeled isotopomers and metabolites of GTS-21, a partial alpha7 nicotinic cholinergic agonist drug.Potential state-selective hydrogen bond formation can modulate activation and desensitization of the α7 nicotinic acetylcholine receptor'Old drugs for new applications': can orthopedic research benefit from this strategy?Point-to-point ligand-receptor interactions across the subunit interface modulate the induction and stabilization of conformational states of alpha7 nAChR by benzylidene anabaseines.A positive allosteric modulator of α7 nAChRs augments neuroprotective effects of endogenous nicotinic agonists in cerebral ischaemia.Effects of an alpha7 nicotinic receptor agonist and stress on spatial memory in an animal model of Alzheimer's disease.Activation and desensitization of nicotinic alpha7-type acetylcholine receptors by benzylidene anabaseines and nicotineThe selective alpha7 agonist GTS-21 attenuates cytokine production in human whole blood and human monocytes activated by ligands for TLR2, TLR3, TLR4, TLR9, and RAGE.The therapeutic promise of positive allosteric modulation of nicotinic receptors.Rat neuronal nicotinic acetylcholine receptors containing alpha7 subunit: pharmacological properties of ligand binding and function.3-(2,4-dimethoxybenzylidene)-anabaseine: a promising candidate drug for Alzheimer's disease?Targeting the "cytokine storm" for therapeutic benefit.
P2860
Q21131066-50AD5B82-3EFF-4573-A892-C4AFBF83D5DDQ24656274-DCC324E5-5693-4D13-A63C-B8CDFED8AAC6Q26852967-61DE19B3-C401-4519-AF50-14A436279949Q27657109-EE468F0F-5875-432A-BF0E-BA4047097590Q28287090-057FD8D1-BB5E-4A6E-98E9-52DAA869158DQ30372351-B863E6AC-C90E-4D79-B9F6-0F2A70E5BCE8Q30391389-3ECA36BF-1EEF-4504-B569-50E793323C00Q30392403-7DD37032-34A0-4EA8-ACE9-6D9F184304FEQ30396291-0EC463F4-A0C2-453F-8B1B-EC1E2F28EDC9Q30474904-C42108D2-A4B7-43CD-807B-20B093DBFBE9Q30491841-F99D70D9-AF52-4F94-9210-8A65A2C5FA62Q32176923-8B79E283-D3F4-4B51-B2A6-39119843E778Q33754362-CDE6C355-1084-4C50-A299-B19D3BF6F12DQ34034293-5C154C02-CEE5-41AA-9017-C28990F8931DQ34055765-29DAD24A-58DD-4781-925D-BBA3EC1F84E3Q34168098-31B17C23-01C0-4B6F-8309-D637225DC163Q34266258-5C23A96F-6766-4945-80F6-874879A87CFEQ34322083-08132479-098E-4FA7-B65B-9E9A3DDC9852Q34501147-704F3960-04D5-4573-8C44-2F5EE732BBDEQ34535906-595714D4-D202-41E3-8D0F-84B4C776DDEAQ34561031-87CD4FB9-3550-4291-8240-FBA2656A11F6Q34586463-E4E8E1FB-442D-4D1D-86A9-F2CC75CF1895Q34796673-9C0C858F-4F73-4755-9A21-BE80AF109993Q34868114-079AE758-0BA6-4626-9EB8-31ABA3D1A675Q34926526-D93C3AB2-26E9-42EA-A567-5A9BCB8A80CFQ34952107-DE32ECD1-B986-44D5-AFC5-6BDC3DA3D1FDQ35009475-392756F1-D286-4B3C-ADCC-99675226418AQ35041190-1CA2ED8B-8A1A-4715-97DC-82261DB6B7C3Q35240381-833B5879-F042-47DD-8B83-5DDC4C8D3D12Q36052452-83DBE5A6-B4E0-4A9D-A819-AB368AFB7800Q36056952-E9F502ED-D861-4B12-BDA5-A7C8C7C91113Q36671168-775CBFF2-FCFC-4D48-A709-9340B9DDF5A9Q37122710-CA2205C2-4E78-47D4-895E-BD4689D848EFQ37154745-5C431613-63D5-4BC0-A670-64BF49E3049AQ37168519-CED576E3-43E3-4A05-8EA4-1C36220E7191Q37254561-C380E812-D8E6-42D4-A90F-3B5C432DBA7AQ37695734-AAD72C39-0EF1-4B1D-80E7-AD2B9FA947ADQ37728112-546AE755-B352-4C38-9971-102B192B3E94Q37980865-9EDCB768-52D3-461E-837B-907B20A5E40CQ38071254-925BC6B1-3654-4B87-BB59-B691D886B790
P2860
The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21).
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The brain alpha7 nicotinic rec ...... : studies with DMXBA (GTS-21).
@ast
The brain alpha7 nicotinic rec ...... : studies with DMXBA (GTS-21).
@en
type
label
The brain alpha7 nicotinic rec ...... : studies with DMXBA (GTS-21).
@ast
The brain alpha7 nicotinic rec ...... : studies with DMXBA (GTS-21).
@en
prefLabel
The brain alpha7 nicotinic rec ...... : studies with DMXBA (GTS-21).
@ast
The brain alpha7 nicotinic rec ...... : studies with DMXBA (GTS-21).
@en
P1476
The brain alpha7 nicotinic rec ...... : studies with DMXBA (GTS-21).
@en
P2093
P304
P356
10.1016/S0166-4328(00)00211-4
P407
P577
2000-08-01T00:00:00Z